Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Dec;76(6):2413–2415. doi: 10.1172/JCI112254

Atriopeptin III. A potent natriuretic, diuretic, and hypotensive agent in rats with chronic renal failure.

B R Cole, M A Kuhnline, P Needleman
PMCID: PMC424395  PMID: 2934412

Abstract

Chronic renal failure is frequently associated with volume overload, resulting in hypertension and, in some cases, congestive heart failure. Atriopeptin III (AP III), a 24-amino acid atrial peptide, is a potent vasodilator and natriuretic/diuretic agent in normal rats. An infusion of AP III at 0.2 microgram/kg per min for 60 min produced dramatic responses in animals with chronic renal failure (5/6 nephrectomy 4 wk before study). Systemic blood pressure fell 20% by the end of infusion. A pronounced rise in glomerular filtration rate (24%) was maintained during the infusion period when urine flow rate was stable (35-60 min), even though renal blood flow was unchanged from base line. Urinary volume increased 4.4-fold and sodium excretion increased 9 to 12-fold during the infusion. Fractional excretion of sodium ranged between 9 and 15% in those animals whose initial GFR values were lower than 0.5 ml/min. We conclude that AP III is a potent natriuretic/diuretic agent in rats with reduced renal mass, presumably exerting that effect predominantly through increases in GFR. This agent may well be useful in the treatment of volume overload in patients with chronic renal failure.

Full text

PDF
2413

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Currie M. G., Geller D. M., Cole B. R., Boylan J. G., YuSheng W., Holmberg S. W., Needleman P. Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. Science. 1983 Jul 1;221(4605):71–73. doi: 10.1126/science.6857267. [DOI] [PubMed] [Google Scholar]
  2. Currie M. G., Geller D. M., Cole B. R., Siegel N. R., Fok K. F., Adams S. P., Eubanks S. R., Galluppi G. R., Needleman P. Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science. 1984 Jan 6;223(4631):67–69. doi: 10.1126/science.6419347. [DOI] [PubMed] [Google Scholar]
  3. DAMADIAN R. V., SHWAYRI E., BRICKER N. S. ON THE EXISTENCE OF NON-URINE FORMING NEPHRONS IN THE DISEASED KIDNEY OF THE DOG. J Lab Clin Med. 1965 Jan;65:26–39. [PubMed] [Google Scholar]
  4. Geller D. M., Currie M. G., Wakitani K., Cole B. R., Adams S. P., Fok K. F., Siegel N. R., Eubanks S. R., Galluppi G. R., Needleman P. Atriopeptins: a family of potent biologically active peptides derived from mammalian atria. Biochem Biophys Res Commun. 1984 Apr 30;120(2):333–338. doi: 10.1016/0006-291x(84)91258-0. [DOI] [PubMed] [Google Scholar]
  5. Huang C. L., Lewicki J., Johnson L. K., Cogan M. G. Renal mechanism of action of rat atrial natriuretic factor. J Clin Invest. 1985 Feb;75(2):769–773. doi: 10.1172/JCI111759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaufman J. M., DiMeola H. J., Siegel N. J., Lytton B., Kashgarian M., Hayslett J. P. Compensatory adaptation of structure and function following progressive renal ablation. Kidney Int. 1974 Jul;6(1):10–17. doi: 10.1038/ki.1974.72. [DOI] [PubMed] [Google Scholar]
  7. Keeler R. The effects of "dead space" and urine flow changes on measurements of glomerular filtration rate by clearance methods. Can J Physiol Pharmacol. 1983 Apr;61(4):435–438. doi: 10.1139/y83-066. [DOI] [PubMed] [Google Scholar]
  8. Robson A. M., Mor J., Root E. R., Jager B. V., Shankel S. W., Ingelfinger J. R., Kienstra R. A., Bricker N. S. Mechanism of proteinuria in nonglomerular renal disease. Kidney Int. 1979 Sep;16(3):416–429. doi: 10.1038/ki.1979.145. [DOI] [PubMed] [Google Scholar]
  9. Shankel S. W., Robson A. M., Bricker N. S. On the mechanism of the splay in the glucose titration curve in advanced experimental renal disease in the rat. J Clin Invest. 1967 Feb;46(2):164–172. doi: 10.1172/JCI105519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Thibault G., Garcia R., Carrier F., Seidah N. G., Lazure C., Chrétien M., Cantin M., Genest J. Structure-activity relationships of atrial natriuretic factor (ANF). I. Natriuretic activity and relaxation of intestinal smooth muscle. Biochem Biophys Res Commun. 1984 Dec 28;125(3):938–946. doi: 10.1016/0006-291x(84)91374-3. [DOI] [PubMed] [Google Scholar]
  11. WHITE R. P., SAMSON F. E., Jr Determination of inulin in plasma and urine by use of anthrone. J Lab Clin Med. 1954 Mar;43(3):475–478. [PubMed] [Google Scholar]
  12. Wakitani K., Cole B. R., Geller D. M., Currie M. G., Adams S. P., Fok K. F., Needleman P. Atriopeptins: correlation between renal vasodilation and natriuresis. Am J Physiol. 1985 Jul;249(1 Pt 2):F49–F53. doi: 10.1152/ajprenal.1985.249.1.F49. [DOI] [PubMed] [Google Scholar]
  13. Wakitani K., Oshima T., Loewy A. D., Holmberg S. W., Cole B. R., Adams S. P., Fok K. F., Currie M. G., Needleman P. Comparative vascular pharmacology of the atriopeptins. Circ Res. 1985 Apr;56(4):621–627. doi: 10.1161/01.res.56.4.621. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES